What Happened?
Gaithersburg, MD-based Novavax Promoted John Trizzino as Executive Vice President, Chief Commercial Officer, Chief Business Officer and Interim Chief Financial Officer
About the Company
Novavax, Inc. (Nasdaq: NVAX), a clinical-stage biopharmaceutical company, employs its cutting-edge technology to create next-generation vaccines to prevent serious infectious diseases, such as pandemic and seasonal influenza and respiratory syncytial virus (RSV). The company’s proprietary virus-like-particle (VLP) technology and single-use bioprocessing system enable rapid vaccine development and production where and when they are needed, worldwide. The company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India. Additional information about Novavax is available on the company’s website
About the Person
John Trizzino is Executive Vice President, Chief Commercial Officer, Chief Business Officer and Interim Chief Financial Officer at Novavax. Previously, John held various senior HR leadership roles in the industry.
Info Source
News
Short Profile